Sargent Investment Group LLC Grows Stock Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Sargent Investment Group LLC increased its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 10.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 4,650 shares of the exchange traded fund’s stock after acquiring an additional 450 shares during the period. Sargent Investment Group LLC’s holdings in SPDR S&P Biotech ETF were worth $431,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in XBI. Avoro Capital Advisors LLC acquired a new position in shares of SPDR S&P Biotech ETF in the 4th quarter valued at $396,844,000. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in SPDR S&P Biotech ETF by 30.3% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,136,000 shares of the exchange traded fund’s stock valued at $297,575,000 after purchasing an additional 730,000 shares during the last quarter. Jane Street Group LLC raised its position in SPDR S&P Biotech ETF by 68.7% in the first quarter. Jane Street Group LLC now owns 961,082 shares of the exchange traded fund’s stock valued at $91,197,000 after purchasing an additional 391,333 shares during the period. Bessemer Group Inc. lifted its stake in SPDR S&P Biotech ETF by 1.7% during the first quarter. Bessemer Group Inc. now owns 922,871 shares of the exchange traded fund’s stock worth $87,572,000 after purchasing an additional 15,794 shares in the last quarter. Finally, Mirae Asset Securities USA Inc. purchased a new position in shares of SPDR S&P Biotech ETF during the second quarter worth $55,626,000.

SPDR S&P Biotech ETF Trading Up 0.1 %

XBI stock opened at $101.28 on Tuesday. The business’s fifty day moving average price is $98.65 and its 200 day moving average price is $93.87. SPDR S&P Biotech ETF has a 12-month low of $63.80 and a 12-month high of $103.52. The company has a market capitalization of $7.72 billion, a PE ratio of 11.47 and a beta of 1.11.

SPDR S&P Biotech ETF Profile

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Recommended Stories

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.